CD19 and systemic lupus erythematosus: More than 20 phase I or phase I/II clinical trials are enrolling SLE patients using anti‐CD19 CAR‐T‐cell therapies, such as NCT05765006 [208] and NCT06189157 [209], which may offer more convincing evidence of long‐term remission in larger populations in the future.